Skip to main navigation Skip to search Skip to main content

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

  • Mingfeng Zhang
  • , Zhaoming Wang
  • , Ofure Obazee
  • , Jinping Jia
  • , Erica J. Childs
  • , Jason Hoskins
  • , Gisella Figlioli
  • , Evelina Mocci
  • , Irene Collins
  • , Charles C. Chung
  • , Christopher Hautman
  • , Alan A. Arslan
  • , Laura Beane-Freeman
  • , Paige M. Bracci
  • , Julie Buring
  • , Eric J. Duell
  • , Steven Gallinger
  • , Graham G. Giles
  • , Gary E. Goodman
  • , Phyllis J. Goodman
  • Aruna Kamineni, Laurence N. Kolonel, Matthew H. Kulke, Núria Malats, Sara H. Olson, Howard D. Sesso, Kala Visvanathan, Emily White, Wei Zheng, Christian C. Abnet, Demetrius Albanes, Gabriella Andreotti, Lauren Brais, H. Bas Bueno-de-Mesquita, Daniela Basso, Sonja I. Berndt, Marie Christine Boutron-Ruault, Maarten F. Bijlsma, Hermann Brenner, Laurie Burdette, Daniele Campa, Neil E. Caporaso, Gabriele Capurso, Giulia Martina Cavestro, Michelle Cotterchio, Eithne Costello, Joanne Elena, Ugo Boggi, J. Michael Gaziano, Maria Gazouli, Edward L. Giovannucci, Michael Goggins, Myron Gross, Christopher A. Haiman, Manal Hassan, Kathy J. Helzlsouer, Nan Hu, David J. Hunter, Elzbieta Iskierka-Jazdzewska, Mazda Jenab, Rudolf Kaaks, Timothy J. Key, Kay Tee Khaw, Eric A. Klein, Manolis Kogevinas, Vittorio Krogh, Juozas Kupcinskas, Robert C. Kurtz, Maria T. Landi, Stefano Landi, Loic Le Marchand, Andrea Mambrini, Satu Mannisto, Roger L. Milne, Rachel E. Neale, Ann L. Oberg, Salvatore Panico, Alpa V. Patel, Petra H.M. Peeters, Ulrike Peters, Raffaele Pezzilli, Miquel Porta, Mark Purdue, J. Ramón Quiros, Elio Riboli, Nathaniel Rothman, Aldo Scarpa, Ghislaine Scelo, Xiao Ou Shu, Debra T. Silverman, Pavel Soucek, Oliver Strobel, Malin Sund, Ewa Malecka-Panas, Philip R. Taylor, Francesca Tavano, Ruth C. Travis, Mark Thornquist, Anne Tjønneland, Geoffrey S. Tobias, Dimitrios Trichopoulos, Yogesh Vashist, Pavel Vodicka, Jean Wactawski-Wende, Nicolas Wentzensen, Herbert Yu, Kai Yu, Anne Zeleniuch-Jacquotte, Charles Kooperberg, Harvey A. Risch, Eric J. Jacobs, Donghui Li, Charles Fuchs, Robert Hoover, Patricia Hartge, Stephen J. Chanock, Gloria M. Petersen, Rachael S. Stolzenberg-Solomon, Brian M. Wolpin, Peter Kraft, Alison P. Klein, Federico Canzian, Laufey T. Amundadottir
  • National Institutes of Health
  • Leidos Inc
  • St. Jude Children Research Hospital
  • German Cancer Research Center
  • Johns Hopkins University
  • New York University
  • University of California at San Francisco
  • Brigham and Women’s Hospital
  • Institute Catala Oncologia
  • University of Toronto
  • Cancer Council Victoria
  • University of Melbourne
  • Monash University
  • Fred Hutchinson Cancer Research Center
  • Southwest Oncology Group Statistical Center
  • Group Health Cooperative
  • University of Hawai'i at Mānoa
  • Dana-Farber Cancer Institute
  • Spanish National Cancer Research Centre (CNIO)
  • Memorial Sloan-Kettering Cancer Center
  • Harvard University
  • University of Washington
  • Vanderbilt University
  • National Institute of Public Health and the Environment
  • Imperial College London
  • University of Malaya
  • Azienda Ospedaliera di Padova
  • Institut national de la santé et de la recherche médicale
  • Université Paris-Saclay
  • IGR
  • University of Amsterdam
  • University of Pisa
  • University of Rome La Sapienza
  • Vita-Salute San Raffaele University
  • Cancer Care Ontario
  • University of Liverpool
  • University and University Hospital of Pisa
  • VA Medical Center
  • National and Kapodistrian University of Athens
  • University of Minnesota Twin Cities
  • University of Southern California
  • University of Texas MD Anderson Cancer Center
  • Medical University of Łódź
  • International Agency for Research on Cancer
  • University of Oxford
  • University of Cambridge
  • Cleveland Clinic Foundation
  • (ISGlobal) Instituto de Salud Global de Barcelona
  • Hospital del Mar
  • University of West Attica
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Lithuanian University of Health Sciences
  • Oncology Department
  • National Institute for Health and Welfare
  • Queensland Institute of Medical Research
  • Mayo Clinic Rochester, MN
  • University of Naples Federico II
  • American Cancer Society
  • Utrecht University
  • Pancreas Unit, Department of Digestive Diseases and Internal Medicine, SantOrsola-Malpighi Hospital
  • Autonomous University of Barcelona
  • Centro de Investigación Biomédicaen Red de Epidemiología y Salud Pública (CIBERESP)
  • Public Health and Participation Directorate
  • University and Hospital Trust of Verona
  • Charles University
  • Heidelberg University 
  • Umeå University
  • IRCCS Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG)
  • Danish Cancer Society
  • Academy of Athens
  • Helenic Health Foundation
  • University of Hamburg
  • Czech Academy of Sciences
  • Yale University

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Abstract

Genome-wide association studies (GWAS) have identified common pancreatic cancer susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify new susceptibility variants, we performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS. This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10-15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10-9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10-8). These SNPs represent independent risk variants at previously identified pancreatic cancer risk loci on chr1q32.1 (NR5A2), chr8q24.21 (MYC) and chr5p15.33 (CLPTM1L-TERT) as per analyses conditioned on previously reported susceptibility variants. We assessed expression of candidate genes at the three risk loci in histologically normal (n = 10) and tumor (n = 8) derived pancreatic tissue samples and observed a marked reduction of NR5A2 expression (chr1q32.1) in the tumors (fold change -7.6, P = 5.7x10-8). This finding was validated in a second set of paired (n = 20) histologically normal and tumor derived pancreatic tissue samples (average fold change for three NR5A2 isoforms -31.3 to -95.7, P = 7.5x10-4-2.0x10-3). Our study has identified new susceptibility variants independently conferring pancreatic cancer risk that merit functional follow-up to identify target genes and explain the underlying biology.

Original languageEnglish
Pages (from-to)66328-66343
Number of pages16
JournalOncotarget
Volume7
Issue number41
DOIs
StatePublished - 2016

Keywords

  • Fine-mapping
  • GWAS
  • Imputation
  • NR5A2
  • Pancreatic cancer

Fingerprint

Dive into the research topics of 'Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21'. Together they form a unique fingerprint.

Cite this